 |
|
Researcher Profile - Rajiv Tandon |
|
|
|
| First Name: | Rajiv | | Last Name: | Tandon | | Title: | Chief of Psychiatry | | Advanced Degrees: | MD | | Affiliation: | State of Florida Program of Mental Health | | Street Address 1: | 1317 Winewood Boulevard | | Street Address 2: | Building 6, Room 235 | | City: | Tallahassee | | State/Province: | FL | | Zip/Postal Code: | 32309 | Country/Territory: | U.S.A. | | Phone: | 850-921-0919 | | Fax: | 850-487-1307 | | Email Address: |  |
Disclosure:
(view policy) |
Member reports no financial or other potential conflicts of interest. [Last Modified: 20 October 2005]
|
|
|
View all comments by Rajiv Tandon
|
Chemistry/pharmacology, Clinical trials, Pharamacology, Phenomenology/diagnosis
|
State Government, University
|
Rajiv Tandon is currently the Chief of Psychiatry, Florida Department of Children and Families. He was on the faculty of the Department of Psychiatry at the University of Michigan Medical Center, Ann Arbor, Michigan, from 1987-2004, where he was a tenured Professor of Psychiatry. He is a member of the Board of Directors of the National Schizophrenia Foundation and a member of the Scientific Council of the National Alliance for the Mentally Ill. He was a member of State of Michigan Mental Health Commission in 2003-2004. Dr Tandon has authored 250 scientific publications and given over 500 national and international scientific presentations. He has received several awards for research and teaching in schizophrenia, including the American Psychiatric Association Young Psychiatrist Researcher of the Year award in 1993, the inaugural NARSAD Gerald Klerman award in 1995, and the 1997 FuturPsych award for outstanding achievement in schizophrenia research. He has been included in every edition of THE BEST DOCTORS IN AMERICA since 1993. |
1. Tandon R, Greden JF : Cholinergic hyperactivity and negative schizophrenic symptoms : A model of dopaminergic/cholinergic interactions in schizophrenia. Archives of General Psychiatry. 46: 745-753, 1989.
2. Tandon R, Mann N, Eisner B, Coppard N : Effect of anticholinergic medication on
positive and negative symptoms in medication-free schizophrenic patients. Psychiatry Research, 31: 235-241, 1990.
3. Tandon R, Mazzara C, DeQuardo J, Craig KA, Meador-Woodruff JH, Goldman R, Greden JF : Dexamethasone suppression test in schizophrenia : Relationship to symptomatology, ventricular enlargement, and outcome. Biological Psychiatry, 29: 953-964, 1991.
4. Tandon R, Shipley J, Taylor S, Greden JF, Eiser A, DeQuardo J, Goodson J : Electroencephalographic sleep abnormalities in schizophrenia : Relationship to positive/negative symptoms and prior neuroleptic treatment, Archives of General Psychiatry, 49: 185-194, 1992.
5. Tandon R, Goldman R, DeQuardo JR, Perez M, Goodson J, Jibson M: Covariance of positive and negative symptoms during clozapine treatment in schizophrenia. Journal of Psychiatric Research 27: 341-347, 1993.
6. Tandon R, Milner K, Jibson M: Antipsychotics from theory to practice: Integrating clinical and basic data. Journal of Clinical Psychiatry, 60 [Suppl 8]: 21-28, 1999.
7. Tandon R, Taylor SF, DeQuardo JR, Shipley JE, Eiser A, Jibson MD: The cholinergic system in schizophrenia reconsidered: Anticholinergic modulation of sleep and symptom profiles. Neuropsychopharmacology, 22: S189-202, 1999.
8. Tandon R: Moving beyond findings: concepts and model-building in schizophrenia.
Journal of Psychiatric Research, 33: 467-471, 1999.
9. Tandon R, DeQuardo JR, Taylor SF, McGrath M, Jibson MD, Eiser A, Goldman M: Psychotic phasic and deficit enduring subtypes of negative symptoms: Biological markers and relationship to outcome. Schizophrenia Research, 45: 191-201, 2000. (Erratum published in 51:185)
10. Tandon R, Fleischhacker WW: Comparative efficacy of antipsychotics in the treatment of schizophrenia: A critical assessment. Schizophrenia Research, 79: 145-155, 2005.
|
Fleischhacker WW, Keet IPM, Kahn RS (2005). The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial. Schizophrenia Research, 78: 147-156.
Lieberman JA, Stroup ST, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 353: 1209-1223.
Fanous AH, van den Oord EJ, Riley BP et al. (2005). Relationship between a high risk haplotype in the DTNBP1 (dysbindin) gene and clinical features of schizophrenia. Am J Psychiatry, 162: 1824-1832.
|
|
|
|
|
|
